Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (537) clinical trials

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...

Phase

Alzheimer’s disease (AD) is the most common cause of dementia. The deposition of extracellular amyloid plaques in the brain is a hallmark pathological finding in AD. These amyloid plaques are primarily composed of Aβ peptides. This study is to evaluate crenezumab, a monoclonal antibody, that has been shown to inhibit ...

Phase

Are you caring for someone with Alzheimer's disease? If so, we need your help! We need individuals 50 years of age or older to participate in an Alzheimer’s disease research study. Eligible participants will receive study-related care, monitoring and investigational medication or placebo. For more information, please call Meridien Research ...

Phase N/A

An evaluation of an imaging agent used in PET scans to detect changes in the brain that occur in individuals with Alzheimer's disease compared to healthy volunteers.

Phase N/A

An exploratory, paired biomarker study in subjects with Alzheimer's disease vs. healthy subjects

Phase N/A

This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease, amyotrophic lateral sclerosis, brain injury, Huntington's Disease, multiple sclerosis, Parkinson's Disease, post-stroke, spinal cord injury.

Phase N/A

Primary objective: to evaluate the efficacy of AZD3293 on cognitive and functional outcomes in patients with early Alzheimer’s disease (AD) as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score. Early AD is defined as the continuum of patients with mild cognitive impairment (MCI) due to AD ...

Phase N/A

Eli Lilly and Company (Lilly) is developing LY3202626, a synthetic small molecule which is a potent inhibitor of β-site amyloid precursor protein (APP)-cleaving enzyme [BACE]1, for the treatment of Alzheimer’s disease (AD). It is hypothesized that inhibition of BACE1 may slow or inhibit the progression of AD. Study I7X-MC-LLCF (LLCF), ...

Phase

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a ...

Phase